Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bayer Aktienges ADR (OP: BAYRY )

5.135 +0.045 (+0.88%)
Streaming Delayed Price Updated: 12:11 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,217,137
Open 5.080
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 5.090
Today's Range 5.080 - 5.170
52wk Range 5.050 - 9.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies. 
Via Benzinga
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat

Performance

YTD
-45.26%
-45.26%
1 Month
-26.85%
-26.85%
3 Month
-33.14%
-33.14%
6 Month
-31.35%
-31.35%
1 Year
-42.43%
-42.43%

More News

Read More
Bayer Seeks European Approval For Its Menopause Drug
Via Benzinga
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Via Benzinga
Week In Review: Zenas Raises $259 Million In IPO
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Via Investor's Business Daily
“Signing Day Sports, Inc. (NYSE American: SGN) Soars in Pre-Market on Acquisition News – see more penny stocks inside….”
Via AB Newswire
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study
Via Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Via Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Via Benzinga
BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
Via Benzinga
Topics Lawsuit
Exposures Financial Glyphosate Legal
ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
Via MarketBeat
Topics Cannabis
Exposures Cannabis
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
Via InvestorPlace
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
Via Benzinga
Exposures Glyphosate
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Via Benzinga
Topics Data Breach
Exposures Information Security
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Via Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned
Via Benzinga
Exposures Glyphosate
Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.